Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.55 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7220892 | 1.00 | DRD2 (0.55) | DRD2CACNA1HCA12CA1CA2 | |
| SCHEMBL4024516 | 0.98 | DRD2 (0.56) | DRD2CACNA1HCA12CA1CA2 | |
| SCHEMBL24172673 | 0.95 | DRD2 (0.56) | DRD2CACNA1HCA12CA1CA2 | |
| SCHEMBL31301250 | 0.95 | DRD2 (0.56) | DRD2CACNA1HCA12CA1CA2 | |
| SCHEMBL31301242 | 0.91 | DRD2 (0.63) | DRD2CACNA1HEPHX1MEN1KMT2A | |
| SCHEMBL4119702 | 0.91 | EPHX1 (0.49) | DRD2CACNA1HCA12CA1CA2 | |
| SCHEMBL4743239 | 0.90 | ACHE (0.58) | DRD2ACHEBACE1MEN1KMT2A | |
| SCHEMBL4118080 | 0.89 | DRD2 (0.49) | DRD2CACNA1HEPHX1ACHEBACE1 | |
| SCHEMBL31596990 | 0.89 | DRD2 (0.58) | DRD2ACHEBACE1MEN1KMT2A | |
| SCHEMBL21142634 | 0.88 | DRD2 (0.52) | DRD2CACNA1HCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109134350-A | Donepezil-BHT heterozygote, preparation method and its for treating Alzheimer's disease | 中国药科大学 | 2019-01-04 | — | — | CN | claimed |
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023007009-A1 | PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-02-02 | — | — | WO | disclosed |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2022-06-07 | — | — | US | disclosed |
| CN-108707139-B | Aminopyrimidine compound and preparation method and application thereof | 北京鞍石生物科技有限责任公司 | 2021-04-06 | — | — | CN | disclosed |
| US-10669305-B2 | C-3 novel triterpenone with C-28 urea derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2020-06-02 | — | — | US | disclosed |
| EP-3640248-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-04-22 | — | — | EP | disclosed |
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-03-19 | — | — | US | disclosed |
| CN-108707139-A | Amino-metadiazine compound and its preparation method and application | 北京浦润奥生物科技有限责任公司 | 2018-10-26 | — | — | CN | disclosed |
| WO-2017064628-A1 | C-3 NOVEL TRITERPENONE WITH C-28 UREA DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-04-20 | — | — | WO | disclosed |
| US-9388137-B2 | Quaternized amines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388137-B2 | Quaternized amines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20140309228-A1 | QUATERNIZED AMINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309228-A1 | QUATERNIZED AMINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-10-16 | — | — | US | disclosed |
| US-8569313-B2 | Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| WO-2013064884-A1 | QUATERNIZED AMINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-05-10 | — | — | WO | disclosed |
| EP-2132174-B1 | META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS | MEDICINES CO LEIPZIG GMBH (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20100305090-A1 | META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| EP-2132174-A1 | META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS | The Medicines Company (Leipzig) GmbH (DE) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008107176-A1 | META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305090-A1 | META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS | MMP7, DNPEP, METAP1 | DRD2 4698/4885CACNA1H 4338/4885CA12 1918/4885 |
| US-20140309228-A1 | QUATERNIZED AMINES AS SODIUM CHANNEL BLOCKERS | CACNA1A, SCN1B, SCN1A | DRD2 651/4885CACNA1H 105/4885CA12 2879/4885 |
| US-10669305-B2 | C-3 novel triterpenone with C-28 urea derivatives as HIV inhibitors | CCR3, CCND3, UBE2D3 | DRD2 2756/4885CACNA1H 4284/4885CA12 2101/4885 |
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, EGFR | DRD2 3830/4885CACNA1H 4476/4885CA12 4587/4885 |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | WEE1, WEE2, EGFR | DRD2 3830/4885CACNA1H 4476/4885CA12 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.